# Tenax Therapeutics, Inc.

Organization · id `cardio:org-tenax-therapeutics-inc` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Tenax+Therapeutics%2C+Inc.>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Tenax Therapeutics, Inc.
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF (`cardio:ct-nct05983250`)
- Sponsors: LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 (`cardio:ct-nct07288398`)
- Sponsors: Long-Term Open-Label Extension Study of Oral Levosimendan (`cardio:ct-nct07436689`)

## Provenance

Content hash: fe9839c9a52f5e6e0fc7bda778d6c625bac457d5b33dc7bd857e886b2578ba66
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
